Regional anticoagulation with citrate has been found to be superior to heparin in terms of biocompatibility, and numerous protocols for regional citrate anticoagulation have been published, while a consensus on the target concentration of ionized calcium (Ca2+) in the extracorporeal circuit has not been reached so far.
Methods
The aim of this in vitro study was to assess the impact of different citrate concentrations on coagulation as well as on complement activation and cytokine secretion and to investigate the impact of ionized magnesium (Mg2+) on these parameters.
Results
We found that citrate effectively reduced coagulation, complement activation, and cytokine secretion in a dose-dependent manner and that a target Ca2+ concentration of 0.2–0.25 mM was required for efficient anticoagulation. Mg2+ triggered complement activation as well as interleukin (IL)-1β secretion in lipopolysaccharide (LPS)-stimulated whole blood in a dose-dependent manner and independently of Ca2+. Additionally, it was found to reduce activated clotting time (ACT) in samples with low Ca2+ levels, but not at physiological Ca2+.
Conclusions
Taken together, our data support the notion that regional citrate anticoagulation results in decreased release of inflammatory mediators in the extracorporeal circuit, requiring the depletion of both, Ca2+ and Mg2+.
PalssonR., NilesJ.L.Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int.1999; 55(5): 1991–1997.
2.
RidelC., MercadalL., BénéB., HamaniA., DerayG., PetitclercT.Regional citrate anticoagulation during hemodialysis: a simplified procedure using Duocart biofiltration. Blood Purif.2005; 23(6): 473–480.
3.
FlaniganM.J., PillsburyL., SadewasserG., LimV.S.Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis.1996; 27(4): 519–524.
4.
CubattoliL., TeruzziM., CormioM., LampatiL., PesentiA.Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs.2007; 30(3): 244–252.
5.
KalbR., KramR., MorgeraS., SlowinskiT., Kindgen-MillesD.Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial.2013; 17(2): 202–212.
6.
BaiM., ZhouM., HeL.Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med.2015; 41(12): 2098–2110.
SwartzR., PaskoD., OTooleJ., StarmannB.Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol.2004; 61(2): 134–143.
9.
BagshawS.M., LauplandK.B., BoiteauP.J., Godinez-LunaT.Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care.2005; 20(2): 155–161.
10.
MonchiM., BerghmansD., LedouxD., CanivetJ.L., DuboisB., DamasP.Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med.2004; 30(2): 260–265.
11.
BöhlerJ., DonauerJ., BirmelinM., SchollmeyerP.J., HörlW.H.Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes. Nephrol Dial Transplant.1993; 8(12): 1359–1365.
12.
BöhlerJ., SchollmeyerP., DresselB., DobosG., HörlW.H.Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol.1996; 7(2): 234–241.
13.
BosJ.C., GrootemanM.P., van HouteA.J., SchoorlM., van LimbeekJ., NubéM.J.Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant.1997; 12(7): 1387–1393.
14.
GrittersM., GrootemanM.P., SchoorlM.Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant.2006; 21(1): 153–159.
15.
SchilderL., NurmohamedS.A., ter WeeP.M.Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol.2014; 15: 19.
16.
GabuttiL., FerrariN., MombelliG., KellerF., MaroneC.The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol.2004; 17(6): 819–825.
Oudemans-van StraatenH.M., BosmanR.J., KoopmansM.Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med.2009; 37(2): 545–552.
19.
HetzelG.R., SchmitzM., WissingH.Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant.2011; 26(1): 232–239.
20.
SchilderL., NurmohamedS.A., ter WeeP.M.Effect of anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Cytokine.2012; 60(3): 601–607.
21.
MorabitoS., PistolesiV., TritapepeL.Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care.2012; 16(3): R111.
22.
OpatrnýK., RichtrováP., PolanskáK.Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs.2007; 31(3): 200–207.
BromanM., KlarinB., SandinK.Simplified citrate anticoagulation for CRRT without calcium replacement. ASAIO J.2015; 61(4): 437–442.
25.
SchneiderM., LiefeldtL., SlowinskiT., PetersH., NeumayerH.H., MorgeraS.Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure. Int J Artif Organs.2008; 31(1): 43–48.
26.
KutsogiannisD.J., GibneyR.T., StolleryD., GaoJ.Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int.2005; 67(6): 2361–2367.
27.
MorgeraS., ScholleC., VossG.Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract.2004; 97(4): c131–c136.
28.
SlowinskiT., MorgeraS., JoannidisM.Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care.2015; 19: 349.
29.
ParkJ.S., KimG.H., KangC.M., LeeC.H.Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med.2011; 26(1): 68–75.
30.
KreuzerM., AhlenstielT., KanzelmeyerN., EhrichJ.H., PapeL.Regional citrate anticoagulationa safe and effective procedure in pediatric apheresis therapy. Pediatr Nephrol.2011; 26(1): 127–132.
31.
SheuJ.R., HsiaoG., ShenM.Y.Mechanisms involved in the antiplatelet activity of magnesium in human platelets. Br J Haematol.2002; 119(4): 1033–1041.
32.
NaH.S., ChungY.H., HwangJ.W., DoS.H.Effects of magnesium sulphate on postoperative coagulation, measured by rotational thromboelastometry (ROTEM®). Anaesthesia.2012; 67(8): 862–869.
33.
KangW.S., YunH.J., HanS.J.The effects of magnesium on the course of atrial fibrillation and coagulation in patients with atrial fibrillation undergoing mitral valve annuloplasty. Korean J Anesthesiol.2011; 61(3): 210–215.
34.
JanssenM.J., HuijgensP.C., BoumanA.A., OeP.L., van der MeulenJ.Citrate anticoagulation and divalent cations in hemodialysis. Blood Purif.1994; 12(6): 308–316.
35.
PerssonE., OstergaardA.Mg2+ binding to the Gla domain of factor X influences the interaction with tissue factor. J Thromb Haemost.2007; 5(9): 1977–1978.
36.
StegmayrB., KlinkmannH.Dieter Falkenhagen (1942–2015): a multifaceted scientist. Int J Artif Organs.2015; 38(11): 617–623.
WeissR., FischerM.B., WeberV.The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis. J Clin Apher.2016. doi 10.1002/jca.21519.
39.
KramerL., BauerE., JoukhadarC.Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med.2003; 31(10): 2450–2455.
40.
KreuzerM., AhlenstielT., KanzelmeyerN., EhrichJ.H., PapeL.Management of regional citrate anticoagulation in pediatric high-flux dialysis: activated coagulation time versus post-filter ionized calcium. Pediatr Nephrol.2010; 25(7): 1305–1310.
41.
StroblK., HartmannJ., WallnerM., BrandlM., FalkenhagenD.A target-oriented algorithm for citrate-calcium anticoagulation in clinical practice. Blood Purif.2013; 36(2): 136–145.
42.
JamesM.F., RocheA.M.Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth.2004; 18(5): 581–586.
43.
KingW.H., PattenE.D., BeeD.E.An in vitro evaluation of ionized calcium levels and clotting in red blood cells diluted with lactated Ringers solution. Anesthesiology.1988; 68(1): 115–121.
44.
AtaullakhanovF.I., PohilkoA.V., SinauridzeE.I., VolkovaR.I.Calcium threshold in human plasma clotting kinetics. Thromb Res.1994; 75(4): 383–394.
45.
WehrhahnJ., KraftR., HarteneckC., HauschildtS.Transient receptor potential melastatin 2 is required for lipopolysaccharide-induced cytokine production in human monocytes. J Immunol.2010; 184(5): 2386–2393.
46.
LibakoP., NowackiW., RockE., RayssiguierY., MazurA.Phagocyte priming by low magnesium status: input to the enhanced inflammatory and oxidative stress responses. Magnes Res.2010; 23(1): 1–4.
47.
ShogiT., OonoH., NakagawaM., MiyamotoA., IshiguroS., NishioA.Effects of a low extracellular magnesium concentration and endotoxin on IL-1beta and TNF-alpha release from, and mRNA levels in, isolated rat alveolar macrophages. Magnes Res.2002; 15(3-4): 147–152.
48.
JamesK.Complement: activation, consequences, and control. Am J Med Technol.1982; 48(9): 735–742.
49.
MesserA.S., VelanderW.H., BajajS.P.Contribution of magnesium in binding of factor IXa to the phospholipid surface: implications for vitamin K-dependent coagulation proteins. J Thromb Haemost.2009; 7(12): 2151–2153.
